Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
GlaxoSmithKline price target raised to 1,630 GBp from 1,540 GBp at Berenberg » 15:22
11/24/21
11/24
15:22
11/24/21
15:22
GSK

GlaxoSmithKline

$41.56 /

-0.03 (-0.07%)

Berenberg analyst Luisa…

Berenberg analyst Luisa Hector raised the firm's price target on GlaxoSmithKline to 1,630 GBp from 1,540 GBp and keeps a Buy rating on the shares.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$41.56 /

-0.03 (-0.07%)

GSK GlaxoSmithKline
$41.56 /

-0.03 (-0.07%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
GSK GlaxoSmithKline
$41.56 /

-0.03 (-0.07%)

GSK GlaxoSmithKline
$41.56 /

-0.03 (-0.07%)

GSK GlaxoSmithKline
$41.56 /

-0.03 (-0.07%)

GSK GlaxoSmithKline
$41.56 /

-0.03 (-0.07%)

Tuesday
Upgrade
Societe Generale upgrades AbbVie to Buy on better than anticipated execution » 07:47
11/23/21
11/23
07:47
11/23/21
07:47
ABBV

AbbVie

$115.68 /

-0.56 (-0.48%)

, BMY

Bristol-Myers

$57.04 /

-0.79 (-1.37%)

Societe Generale analyst…

Societe Generale analyst Justin Smith upgraded AbbVie (ABBV) to Buy from Hold with a price target of $172, up from $111, telling investors that he sees management executing better than he anticipated on two franchises "crucial to its long-term prospects," immuno-inflammation and aesthetics. AbbVie is replacing Bristol Myers Squibb (BMY) as his preferred value call in global large cap pharma given its improved "long-term replacement power," added Smith, who now has "full conviction" in management's long-term guidance for Allergan's aesthetics franchise following the company's Q3 report.

ShowHide Related Items >><<
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
11/17/21 Truist
AbbVie triple data could be pushed back, says Truist
11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

Hot Stocks
Bristol-Myers announces Market Authorization in Europe for Zeposia » 07:01
11/23/21
11/23
07:01
11/23/21
07:01
BMY

Bristol-Myers

$57.04 /

-0.79 (-1.37%)

Bristol Myers Squibb…

Bristol Myers Squibb announced the European Commission has granted a Marketing Authorization for Zeposia, or ozanimod, for the treatment of adults with moderately to severely active ulcerative colitis, or UC, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. Zeposia, an oral medication taken once daily, is a sphingosine 1-phosphate, or S1P, receptor modulator that binds with high affinity selectively to S1P subtypes 1 and 5. Zeposia is the first and only oral S1P receptor modulator approved for UC, and represents a new way of treating this chronic immune-mediated disease.

ShowHide Related Items >><<
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

Monday
On The Fly
Wall Street in Fives - Must Read Lists for Monday » 16:25
11/22/21
11/22
16:25
11/22/21
16:25
ERIC

Ericsson

$10.13 /

-0.795 (-7.28%)

, VG

Vonage

$20.81 /

+4.44 (+27.12%)

, AVYA

Avaya

$22.00 /

+4.02 (+22.36%)

, TSLA

Tesla

$1,156.86 /

+20.35 (+1.79%)

, WMT

Walmart

$144.77 /

+2.37 (+1.66%)

, TWTR

Twitter

$47.31 /

-1.13 (-2.33%)

, ATVI

Activision Blizzard

$62.20 /

-0.17 (-0.27%)

, GFS

GlobalFoundries

$63.83 /

+1.93 (+3.12%)

, BLNK

Blink Charging

$38.20 /

-4.895 (-11.36%)

, TDOC

Teladoc

$109.10 /

-7.79 (-6.66%)

, XEL

Xcel Energy

$66.29 /

+1.18 (+1.81%)

, MNST

Monster Beverage

$90.09 /

+0.79 (+0.88%)

, AAPL

Apple

$161.12 /

+0.57 (+0.36%)

, MVRS

Meta

/

+

, FB

Facebook; also tag MVRS

$341.17 /

-4.19 (-1.21%)

, BA

Boeing

$209.91 /

-4.11 (-1.92%)

, ASTR

Astra

$11.15 /

+1.625 (+17.06%)

, PRVB

Provention Bio

$7.18 /

+0.925 (+14.80%)

, XPEV

XPeng

$47.40 /

+0.54 (+1.15%)

, RIVN

Rivian Automotive

$118.73 /

-9.91 (-7.70%)

, F

Ford

$20.48 /

+1.09 (+5.62%)

, AUPH

Aurinia Pharmaceuticals

$19.65 /

-8.84 (-31.03%)

, CRNC

Cerence

$82.50 /

-21.42 (-20.61%)

, ELYS

Elys Game Technology

$3.32 /

-0.49 (-12.86%)

, QIPT

Quipt Home Medical

$6.77 /

-0.075 (-1.10%)

, FNA

Paragon 28

$20.59 /

-0.53 (-2.51%)

, TWST

Twist Bioscience

$98.22 /

-12.615 (-11.38%)

Get caught up quickly on…

ShowHide Related Items >><<
XPEV XPeng
$47.40 /

+0.54 (+1.15%)

XEL Xcel Energy
$66.29 /

+1.18 (+1.81%)

WMT Walmart
$144.77 /

+2.37 (+1.66%)

VG Vonage
$20.81 /

+4.44 (+27.12%)

TWTR Twitter
$47.31 /

-1.13 (-2.33%)

TWST Twist Bioscience
$98.22 /

-12.615 (-11.38%)

TSLA Tesla
$1,156.86 /

+20.35 (+1.79%)

TDOC Teladoc
$109.10 /

-7.79 (-6.66%)

RIVN Rivian Automotive
$118.73 /

-9.91 (-7.70%)

QIPT Quipt Home Medical
$6.77 /

-0.075 (-1.10%)

PRVB Provention Bio
$7.18 /

+0.925 (+14.80%)

MVRS Meta
/

+

MNST Monster Beverage
$90.09 /

+0.79 (+0.88%)

GFS GlobalFoundries
$63.83 /

+1.93 (+3.12%)

FB Facebook; also tag MVRS
$341.17 /

-4.19 (-1.21%)

F Ford
$20.48 /

+1.09 (+5.62%)

ERIC Ericsson
$10.13 /

-0.795 (-7.28%)

ELYS Elys Game Technology
$3.32 /

-0.49 (-12.86%)

CRNC Cerence
$82.50 /

-21.42 (-20.61%)

BLNK Blink Charging
$38.20 /

-4.895 (-11.36%)

BA Boeing
$209.91 /

-4.11 (-1.92%)

AVYA Avaya
$22.00 /

+4.02 (+22.36%)

AUPH Aurinia Pharmaceuticals
$19.65 /

-8.84 (-31.03%)

ATVI Activision Blizzard
$62.20 /

-0.17 (-0.27%)

ASTR Astra
$11.15 /

+1.625 (+17.06%)

AAPL Apple
$161.12 /

+0.57 (+0.36%)

ERIC Ericsson
$10.13 /

-0.795 (-7.28%)

11/23/21 KeyBanc
Vonage downgraded to Sector Weight from Overweight at KeyBanc
10/25/21 BofA
Ericsson reinstated with an Underperform at BofA
10/20/21 JPMorgan
Ericsson price target lowered to SEK 123 from SEK 125 at JPMorgan
10/20/21 Cowen
Ericsson price target lowered to $18 from $21 at Cowen
VG Vonage
$20.81 /

+4.44 (+27.12%)

11/23/21 Baird
Vonage downgraded to Neutral from Outperform at Baird
11/22/21 Craig-Hallum
Vonage downgraded to Hold from Buy at Craig-Hallum
11/22/21 Jefferies
Jefferies raises Vonage price target to $21, sees high odds acquisition closes
AVYA Avaya
$22.00 /

+4.02 (+22.36%)

11/23/21 Citi
Avaya price target raised to $25 from $24 at Citi
11/12/21 Cowen
Avaya price target lowered to $33 from $40 at Cowen
10/20/21 Barclays
Avaya downgraded to Equal Weight from Overweight at Barclays
10/18/21 JPMorgan
Avaya downgraded to Neutral into 'more modest year' at JPMorgan
TSLA Tesla
$1,156.86 /

+20.35 (+1.79%)

11/19/21 Morgan Stanley
Apple Car would be 'ultimate EV bear case,' says Morgan Stanley
11/19/21 Wedbush
Tesla price target raised to $1,400 from $1,100 at Wedbush
11/17/21 Exane BNP Paribas
Exane BNP Paribas boosts Tesla target to $780, keeps Underpeform rating
11/15/21 Wedbush
GM stock may hit $100 over next 12-18 months in bull case scenario, says Wedbush
WMT Walmart
$144.77 /

+2.37 (+1.66%)

11/19/21
Fly Intel: Top five analyst upgrades
11/19/21 MKM Partners
MKM upgrades Walmart to Buy with $166 target heading into holidays
11/19/21 MKM Partners
Walmart upgraded to Buy from Neutral at MKM Partners
11/18/21 Credit Suisse
Credit Suisse transfers coverage of Walmart
TWTR Twitter
$47.31 /

-1.13 (-2.33%)

11/09/21 Morgan Stanley
Twitter price target lowered to $62 from $68 at Morgan Stanley
11/01/21 Citi
Citi upgrades Snap to Neutral, cuts price target to $53
10/28/21 BMO Capital
Twitter price target lowered to $65 from $70 at BMO Capital
10/28/21 Wells Fargo
Twitter price target lowered to $70 from $82 at Wells Fargo
ATVI Activision Blizzard
$62.20 /

-0.17 (-0.27%)

11/22/21
Fly Intel: Top five analyst downgrades
11/22/21 MKM Partners
Activision Blizzard downgraded to Sell from Neutral at MKM Partners
11/22/21 Truist
Activision Blizzard price target lowered to $74 from $101 at Truist
11/22/21 MKM Partners
Activision Blizzard downgraded to Sell from Neutral at MKM Partners
GFS GlobalFoundries
$63.83 /

+1.93 (+3.12%)

11/22/21
Fly Intel: Top five analyst initiations
11/22/21 HSBC
GlobalFoundries initiated with a Hold at HSBC
11/22/21 BofA
BofA starts GlobalFoundries at Buy, sees 40% upside potential
11/22/21 JPMorgan
GlobalFoundries initiated with an Overweight at JPMorgan
BLNK Blink Charging
$38.20 /

-4.895 (-11.36%)

11/22/21 Cowen
Blink Charging downgraded to Market Perform from Outperform at Cowen
11/15/21
Fly Intel: Top five analyst upgrades
11/15/21 DA Davidson
Blink Charging price target raised to $35 from $31 at DA Davidson
TDOC Teladoc
$109.10 /

-7.79 (-6.66%)

11/23/21 Canaccord
Teladoc price target lowered to $160 from $188 at Canaccord
11/22/21 Stifel
Teladoc price target lowered to $135 from $153 at Stifel
11/22/21 BTIG
Teladoc downgraded to Neutral from Buy at BTIG
XEL Xcel Energy
$66.29 /

+1.18 (+1.81%)

11/22/21
Fly Intel: Top five analyst upgrades
11/21/21 BMO Capital
Xcel Energy upgraded to Outperform from Market Perform at BMO Capital
11/02/21 Mizuho
Xcel Energy price target lowered to $64 from $70 at Mizuho
10/29/21 BofA
Xcel Energy upgraded to Buy at BofA following underperformance
MNST Monster Beverage
$90.09 /

+0.79 (+0.88%)

11/23/21 Morgan Stanley
Full Monster-Constellation combo 'less plausible' than JV, says Morgan Stanley
11/23/21 Citi
Citi 'highly skeptical' Coke would abandon relationship with Monster
11/22/21 Stifel
Monster-Constellation JV makes sense, merger 'less so,' says Stifel
11/02/21 Deutsche Bank
Monster Beverage price target lowered to $105 from $108 at Deutsche Bank
AAPL Apple
$161.12 /

+0.57 (+0.36%)

11/23/21 Credit Suisse
Matterport price target raised to $34 from $25 at Credit Suisse
11/19/21 Morgan Stanley
Morgan Stanley lays out five points to keep in mind on Apple Car
11/18/21 Piper Sandler
Jamf competitive threat from Apple is minimal, says Piper Sandler
MVRS Meta
/

+

11/19/21 JMP Securities
DoubleVerify may see $200M opportunity from Facebook news, says JMP Securities
11/08/21 Stifel
AMD-Meta partnership shows secular growth thesis 'gaining momentum,' says Stifel
10/28/21 Piper Sandler
Facebook name change a 'big, bold and risky bet,' says Piper Sandler
FB Facebook; also tag MVRS
$341.17 /

-4.19 (-1.21%)

11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
11/09/21 Susquehanna
AMD price target raised to $175 from $145 at Susquehanna
BA Boeing
$209.91 /

-4.11 (-1.92%)

11/18/21
Fly Intel: Top five analyst upgrades
11/18/21 JPMorgan
Boeing upgraded to Overweight from Neutral at JPMorgan
11/17/21
Fly Intel: Top five analyst upgrades
11/17/21 Wells Fargo
Wells Fargo upgrades Boeing on positive risk/reward after underperformance
ASTR Astra
$11.15 /

+1.625 (+17.06%)

10/11/21 Deutsche Bank
Astra named short-term investment idea at Deutsche Bank
10/04/21
Fly Intel: Top five analyst initiations
10/04/21 BofA
Astra initiated with an Underperform at BofA
07/27/21 Deutsche Bank
Astra initiated with a Buy at Deutsche Bank
PRVB Provention Bio
$7.18 /

+0.925 (+14.80%)

11/23/21 SMBC Nikko
Provention Bio upgraded to Outperform from Neutral at SMBC Nikko
07/09/21 Chardan
Provention Bio coverage transferred at Chardan
05/28/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
05/25/21 SVB Leerink
Provention Bio briefing documents a positive, says SVB Leerink
XPEV XPeng
$47.40 /

+0.54 (+1.15%)

11/11/21 Citi
XPeng price target raised to $87 from $53.40 at Citi
10/28/21
Fly Intel: Top five analyst initiations
10/28/21 Bernstein
Bernstein starts XPeng at Outperform, sees EVs as 'future' of Chinese autos
10/28/21 Bernstein
XPeng initiated with an Outperform at Bernstein
RIVN Rivian Automotive
$118.73 /

-9.91 (-7.70%)

F Ford
$20.48 /

+1.09 (+5.62%)

11/11/21 Morgan Stanley
Morgan Stanley bumps up Ford price target to $12, stays Underweight
11/02/21 Nomura
Nomura downgrades Ford to Reduce, calls premium valuation 'hard to justify'
11/02/21 Nomura
Ford downgraded to Reduce from Neutral at Nomura
10/29/21 Tigress Financial
Snap-On price target raised to $295 from $289 at Tigress Financial
AUPH Aurinia Pharmaceuticals
$19.65 /

-8.84 (-31.03%)

11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
CRNC Cerence
$82.50 /

-21.42 (-20.61%)

11/23/21 Craig-Hallum
Cerence price target lowered to $135 from $145 at Craig-Hallum
11/23/21 Wedbush
Cerence price target lowered to $115 from $140 at Wedbush
11/23/21 RBC Capital
Cerence price target lowered to $95 from $110 at RBC Capital
10/06/21 RBC Capital
RBC Capital upgraded Cerence to Outperform, sees selloff as overdone
ELYS Elys Game Technology
$3.32 /

-0.49 (-12.86%)

07/26/21 Maxim
Elys Game Technology initiated with a Buy at Maxim
03/10/21
Fly Intel: Top five analyst initiations
03/10/21 H.C. Wainwright
Elys Game Technology initiated with a Buy at H.C. Wainwright
QIPT Quipt Home Medical
$6.77 /

-0.075 (-1.10%)

11/19/21 Canaccord
Quipt Home Medical price target raised to C$11 from C$10 at Canaccord
11/17/21 Stifel
Quipt Home Medical price target raised to C$12.75 from C$12.40 at Stifel
10/20/21 Benchmark
Quipt Home Medical initiated with a Buy at Benchmark
FNA Paragon 28
$20.59 /

-0.53 (-2.51%)

11/22/21 Piper Sandler
Paragon 28 a 'name to own' after strong first public report, says Piper Sandler
11/09/21 Canaccord
Canaccord starts foot & ankle share taker Paragon 28 with a Buy
11/09/21 Needham
Paragon 28 initiated with a Buy at Needham
11/09/21 Canaccord
Paragon 28 initiated with a Buy at Canaccord
TWST Twist Bioscience
$98.22 /

-12.615 (-11.38%)

11/23/21 Baird
Twist Bioscience price target lowered to $113 from $130 at Baird
10/14/21 Cowen
Twist Bioscience coverage transferred at Cowen
08/09/21 Baird
Twist Bioscience price target lowered to $130 from $140 at Baird
06/29/21 William Blair
Twist Bioscience initiated with an Outperform at William Blair
XPEV XPeng
$47.40 /

+0.54 (+1.15%)

XEL Xcel Energy
$66.29 /

+1.18 (+1.81%)

WMT Walmart
$144.77 /

+2.37 (+1.66%)

VG Vonage
$20.81 /

+4.44 (+27.12%)

TWTR Twitter
$47.31 /

-1.13 (-2.33%)

TWST Twist Bioscience
$98.22 /

-12.615 (-11.38%)

TSLA Tesla
$1,156.86 /

+20.35 (+1.79%)

TDOC Teladoc
$109.10 /

-7.79 (-6.66%)

QIPT Quipt Home Medical
$6.77 /

-0.075 (-1.10%)

PRVB Provention Bio
$7.18 /

+0.925 (+14.80%)

MNST Monster Beverage
$90.09 /

+0.79 (+0.88%)

FNA Paragon 28
$20.59 /

-0.53 (-2.51%)

FB Facebook; also tag MVRS
$341.17 /

-4.19 (-1.21%)

F Ford
$20.48 /

+1.09 (+5.62%)

ERIC Ericsson
$10.13 /

-0.795 (-7.28%)

ELYS Elys Game Technology
$3.32 /

-0.49 (-12.86%)

CRNC Cerence
$82.50 /

-21.42 (-20.61%)

BLNK Blink Charging
$38.20 /

-4.895 (-11.36%)

BA Boeing
$209.91 /

-4.11 (-1.92%)

AVYA Avaya
$22.00 /

+4.02 (+22.36%)

AUPH Aurinia Pharmaceuticals
$19.65 /

-8.84 (-31.03%)

ATVI Activision Blizzard
$62.20 /

-0.17 (-0.27%)

AAPL Apple
$161.12 /

+0.57 (+0.36%)

  • 10
    Nov
  • 28
    Oct
  • 15
    Oct
  • 14
    Jan
  • 08
    Jan
  • 09
    Dec
  • 03
    Dec
XPEV XPeng
$47.40 /

+0.54 (+1.15%)

WMT Walmart
$144.77 /

+2.37 (+1.66%)

VG Vonage
$20.81 /

+4.44 (+27.12%)

TWTR Twitter
$47.31 /

-1.13 (-2.33%)

TSLA Tesla
$1,156.86 /

+20.35 (+1.79%)

TDOC Teladoc
$109.10 /

-7.79 (-6.66%)

RIVN Rivian Automotive
$118.73 /

-9.91 (-7.70%)

MVRS Meta
/

+

MNST Monster Beverage
$90.09 /

+0.79 (+0.88%)

FB Facebook; also tag MVRS
$341.17 /

-4.19 (-1.21%)

ERIC Ericsson
$10.13 /

-0.795 (-7.28%)

BLNK Blink Charging
$38.20 /

-4.895 (-11.36%)

BA Boeing
$209.91 /

-4.11 (-1.92%)

AUPH Aurinia Pharmaceuticals
$19.65 /

-8.84 (-31.03%)

ATVI Activision Blizzard
$62.20 /

-0.17 (-0.27%)

AAPL Apple
$161.12 /

+0.57 (+0.36%)

XPEV XPeng
$47.40 /

+0.54 (+1.15%)

WMT Walmart
$144.77 /

+2.37 (+1.66%)

VG Vonage
$20.81 /

+4.44 (+27.12%)

TWTR Twitter
$47.31 /

-1.13 (-2.33%)

TWST Twist Bioscience
$98.22 /

-12.615 (-11.38%)

TSLA Tesla
$1,156.86 /

+20.35 (+1.79%)

TDOC Teladoc
$109.10 /

-7.79 (-6.66%)

RIVN Rivian Automotive
$118.73 /

-9.91 (-7.70%)

PRVB Provention Bio
$7.18 /

+0.925 (+14.80%)

MNST Monster Beverage
$90.09 /

+0.79 (+0.88%)

GFS GlobalFoundries
$63.83 /

+1.93 (+3.12%)

FNA Paragon 28
$20.59 /

-0.53 (-2.51%)

ERIC Ericsson
$10.13 /

-0.795 (-7.28%)

CRNC Cerence
$82.50 /

-21.42 (-20.61%)

AUPH Aurinia Pharmaceuticals
$19.65 /

-8.84 (-31.03%)

ATVI Activision Blizzard
$62.20 /

-0.17 (-0.27%)

ASTR Astra
$11.15 /

+1.625 (+17.06%)

AAPL Apple
$161.12 /

+0.57 (+0.36%)

XPEV XPeng
$47.40 /

+0.54 (+1.15%)

WMT Walmart
$144.77 /

+2.37 (+1.66%)

TWTR Twitter
$47.31 /

-1.13 (-2.33%)

TSLA Tesla
$1,156.86 /

+20.35 (+1.79%)

TDOC Teladoc
$109.10 /

-7.79 (-6.66%)

RIVN Rivian Automotive
$118.73 /

-9.91 (-7.70%)

QIPT Quipt Home Medical
$6.77 /

-0.075 (-1.10%)

MNST Monster Beverage
$90.09 /

+0.79 (+0.88%)

FB Facebook; also tag MVRS
$341.17 /

-4.19 (-1.21%)

F Ford
$20.48 /

+1.09 (+5.62%)

ERIC Ericsson
$10.13 /

-0.795 (-7.28%)

ELYS Elys Game Technology
$3.32 /

-0.49 (-12.86%)

BLNK Blink Charging
$38.20 /

-4.895 (-11.36%)

BA Boeing
$209.91 /

-4.11 (-1.92%)

AVYA Avaya
$22.00 /

+4.02 (+22.36%)

AUPH Aurinia Pharmaceuticals
$19.65 /

-8.84 (-31.03%)

ATVI Activision Blizzard
$62.20 /

-0.17 (-0.27%)

ASTR Astra
$11.15 /

+1.625 (+17.06%)

AAPL Apple
$161.12 /

+0.57 (+0.36%)

AAPL Apple
$161.12 /

+0.57 (+0.36%)

Hot Stocks
Roche's obinutuzumab granted FDA orphan designation » 16:01
11/22/21
11/22
16:01
11/22/21
16:01
RHHBY

Roche

$48.94 /

-0.8089 (-1.63%)

Genentech, a unit of…

Genentech, a unit of Roche, was granted orphan designation from the FDA for obinutuzumab for the treatment of childhood-onset idiopathic nephrotic syndrome, or NS, defined as steroid dependent or frequently relapsing NS, according to a post to the agency's website. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$48.94 /

-0.8089 (-1.63%)

RHHBY Roche
$48.94 /

-0.8089 (-1.63%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
RHHBY Roche
$48.94 /

-0.8089 (-1.63%)

RHHBY Roche
$48.94 /

-0.8089 (-1.63%)

RHHBY Roche
$48.94 /

-0.8089 (-1.63%)

Hot Stocks
Arrowhead enters exclusive license pact with GSK for ARO-HSD » 16:01
11/22/21
11/22
16:01
11/22/21
16:01
ARWR

Arrowhead

$69.78 /

-1.21 (-1.70%)

, GSK

GlaxoSmithKline

$41.34 /

-0.235 (-0.57%)

Arrowhead Pharmaceuticals…

Arrowhead Pharmaceuticals (ARWR) announced that it entered into an exclusive license agreement with GlaxoSmithKline (GSK) under which GSK will develop and commercialize ARO-HSD, Arrowhead's investigational RNA interference therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis. "Genetic studies have shown that HSD17B13 is a compelling therapeutic target for multiple forms of liver disease. Based on the clinical results generated to date, including those recently presented at the 2021 AASLD Liver Meeting, ARO-HSD could have the potential to be the first investigational therapeutic to achieve robust reductions in mRNA and protein levels of hepatic HSD17B13, leading to reductions in ALT, a liver enzyme typically elevated in liver diseases such as NASH," said Christopher Anzalone, Ph.D., Arrowhead's president and CEO. "GSK has a global reach and impressive capabilities in the clinical development and commercialization of important medicines. As the work continues towards progressing further Phase 2 studies and planning Phase 3 studies for ARO-HSD, we believe this agreement with GSK furthers the potential of ARO-HSD as a promising new investigational therapeutic for patients with NASH and other liver diseases. We look forward to enabling GSK to advance ARO-HSD towards the millions of patients worldwide who do not have adequate treatment options." Under the terms of the agreement, Arrowhead will receive an upfront payment of $120M and is eligible for additional payments of $30M at the start of Phase 2 and $100M upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190M at first commercial sale, and up to $590M in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales. GSK will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead. GSK will be wholly responsible for further clinical development and commercialization, outside of Greater China. The transaction is expected to close in the first quarter of 2022, subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$41.34 /

-0.235 (-0.57%)

ARWR Arrowhead
$69.78 /

-1.21 (-1.70%)

ARWR Arrowhead
$69.78 /

-1.21 (-1.70%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
GSK GlaxoSmithKline
$41.34 /

-0.235 (-0.57%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
GSK GlaxoSmithKline
$41.34 /

-0.235 (-0.57%)

ARWR Arrowhead
$69.78 /

-1.21 (-1.70%)

GSK GlaxoSmithKline
$41.34 /

-0.235 (-0.57%)

ARWR Arrowhead
$69.78 /

-1.21 (-1.70%)

GSK GlaxoSmithKline
$41.34 /

-0.235 (-0.57%)

ARWR Arrowhead
$69.78 /

-1.21 (-1.70%)

GSK GlaxoSmithKline
$41.34 /

-0.235 (-0.57%)

ARWR Arrowhead
$69.78 /

-1.21 (-1.70%)

On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:10
11/22/21
11/22
12:10
11/22/21
12:10
VG

Vonage

$20.62 /

+4.25 (+25.96%)

, ERIC

Ericsson

$10.23 /

-0.695 (-6.36%)

, AVYA

Avaya

$21.70 /

+3.72 (+20.69%)

, CRNC

Cerence

$82.95 /

-20.97 (-20.18%)

, TSLA

Tesla

$1,151.58 /

+15.07 (+1.33%)

, MNST

Monster Beverage

$90.25 /

+0.945 (+1.06%)

, STZ

Constellation Brands

$234.69 /

-0.68 (-0.29%)

, STZ.B

Constellation Brands; also tag STZ

$239.26 /

+24.95 (+11.64%)

, ATVI

Activision Blizzard

$60.69 /

-1.68 (-2.69%)

, AAPL

Apple

$163.63 /

+3.075 (+1.92%)

, NFLX

Netflix

$659.68 /

-18.915 (-2.79%)

, MVRS

Meta

/

+

, FB

Facebook; also tag MVRS

$341.07 /

-4.29 (-1.24%)

, ASTR

Astra

$12.11 /

+2.585 (+27.14%)

, PRVB

Provention Bio

$7.26 /

+1.01 (+16.16%)

, XPEV

XPeng

$47.50 /

+0.64 (+1.37%)

, RIVN

Rivian Automotive

$111.43 /

-17.21 (-13.38%)

, F

Ford

$19.90 /

+0.51 (+2.63%)

, AUPH

Aurinia Pharmaceuticals

$20.08 /

-8.41 (-29.52%)

, SR

Spire

$62.47 /

+0.82 (+1.33%)

, ELYS

Elys Game Technology

$3.37 /

-0.44 (-11.55%)

, QIPT

Quipt Home Medical

$6.87 /

+0.03 (+0.44%)

, FNA

Paragon 28

$21.90 /

+0.78 (+3.69%)

, TWST

Twist Bioscience

$100.90 /

-9.935 (-8.96%)

, GFS

GlobalFoundries

$65.00 /

+3.1 (+5.01%)

, BLNK

Blink Charging

$37.94 /

-5.15 (-11.95%)

, TDOC

Teladoc

$108.83 /

-8.06 (-6.90%)

, XEL

Xcel Energy

$66.87 /

+1.76 (+2.70%)

Get caught up quickly on…

ShowHide Related Items >><<
XPEV XPeng
$47.50 /

+0.64 (+1.37%)

XEL Xcel Energy
$66.87 /

+1.76 (+2.70%)

VG Vonage
$20.62 /

+4.25 (+25.96%)

TWST Twist Bioscience
$100.90 /

-9.935 (-8.96%)

TSLA Tesla
$1,151.58 /

+15.07 (+1.33%)

TDOC Teladoc
$108.83 /

-8.06 (-6.90%)

STZ Constellation Brands
$234.69 /

-0.68 (-0.29%)

SR Spire
$62.47 /

+0.82 (+1.33%)

RIVN Rivian Automotive
$111.43 /

-17.21 (-13.38%)

QIPT Quipt Home Medical
$6.87 /

+0.03 (+0.44%)

PRVB Provention Bio
$7.26 /

+1.01 (+16.16%)

NFLX Netflix
$659.68 /

-18.915 (-2.79%)

MVRS Meta
/

+

MNST Monster Beverage
$90.25 /

+0.945 (+1.06%)

F Ford
$19.90 /

+0.51 (+2.63%)

ERIC Ericsson
$10.23 /

-0.695 (-6.36%)

ELYS Elys Game Technology
$3.37 /

-0.44 (-11.55%)

CRNC Cerence
$82.95 /

-20.97 (-20.18%)

BLNK Blink Charging
$37.94 /

-5.15 (-11.95%)

AVYA Avaya
$21.70 /

+3.72 (+20.69%)

AUPH Aurinia Pharmaceuticals
$20.08 /

-8.41 (-29.52%)

ATVI Activision Blizzard
$60.69 /

-1.68 (-2.69%)

ASTR Astra
$12.11 /

+2.585 (+27.14%)

AAPL Apple
$163.63 /

+3.075 (+1.92%)

VG Vonage
$20.62 /

+4.25 (+25.96%)

11/22/21 William Blair
Vonage downgraded to Market Perform from Outperform at William Blair
11/22/21 Northland
Vonage downgraded to Market Perform from Outperform at Northland
11/22/21 Colliers
Vonage downgraded to Neutral from Buy at Colliers
11/05/21 JPMorgan
Vonage upgraded to Overweight from Neutral at JPMorgan
ERIC Ericsson
$10.23 /

-0.695 (-6.36%)

10/25/21 BofA
Ericsson reinstated with an Underperform at BofA
10/20/21 JPMorgan
Ericsson price target lowered to SEK 123 from SEK 125 at JPMorgan
10/20/21 Cowen
Ericsson price target lowered to $18 from $21 at Cowen
10/08/21 Barclays
Ericsson price target raised to SEK 150 from SEK 145 at Barclays
AVYA Avaya
$21.70 /

+3.72 (+20.69%)

11/12/21 Cowen
Avaya price target lowered to $33 from $40 at Cowen
10/20/21 Barclays
Avaya downgraded to Equal Weight from Overweight at Barclays
10/18/21 JPMorgan
Avaya downgraded to Neutral into 'more modest year' at JPMorgan
10/18/21 JPMorgan
Avaya downgraded to Neutral from Overweight at JPMorgan
CRNC Cerence
$82.95 /

-20.97 (-20.18%)

10/06/21 RBC Capital
RBC Capital upgraded Cerence to Outperform, sees selloff as overdone
10/06/21 RBC Capital
Cerence upgraded to Outperform from Sector Perform at RBC Capital
08/16/21 Evercore ISI
Cerence price target raised to $150 from $125 at Evercore ISI
08/10/21 Baird
Cerence price target raised to $135 from $122 at Baird
TSLA Tesla
$1,151.58 /

+15.07 (+1.33%)

11/19/21 Morgan Stanley
Apple Car would be 'ultimate EV bear case,' says Morgan Stanley
11/19/21 Wedbush
Tesla price target raised to $1,400 from $1,100 at Wedbush
11/17/21 Exane BNP Paribas
Exane BNP Paribas boosts Tesla target to $780, keeps Underpeform rating
11/15/21 Wedbush
GM stock may hit $100 over next 12-18 months in bull case scenario, says Wedbush
MNST Monster Beverage
$90.25 /

+0.945 (+1.06%)

11/22/21 Stifel
Monster-Constellation JV makes sense, merger 'less so,' says Stifel
11/02/21 Deutsche Bank
Monster Beverage price target lowered to $105 from $108 at Deutsche Bank
11/01/21
Fly Intel: Top five analyst initiations
11/01/21 Redburn
Monster Beverage initiated with a Neutral at Redburn
STZ Constellation Brands
$234.69 /

-0.68 (-0.29%)

11/01/21 Cantor Fitzgerald
Tilray downgraded to Neutral from Overweight at Cantor Fitzgerald
10/13/21 HSBC
HSBC upgrades Constellation Brands to Buy on ' strong' fundamentals
10/13/21 HSBC
Constellation Brands upgraded to Buy from Hold at HSBC
STZ.B Constellation Brands; also tag STZ
$239.26 /

+24.95 (+11.64%)

ATVI Activision Blizzard
$60.69 /

-1.68 (-2.69%)

11/22/21
Fly Intel: Top five analyst downgrades
11/22/21 MKM Partners
Activision Blizzard downgraded to Sell from Neutral at MKM Partners
11/22/21 Truist
Activision Blizzard price target lowered to $74 from $101 at Truist
11/22/21 MKM Partners
Activision Blizzard downgraded to Sell from Neutral at MKM Partners
AAPL Apple
$163.63 /

+3.075 (+1.92%)

11/19/21 Morgan Stanley
Morgan Stanley lays out five points to keep in mind on Apple Car
11/18/21 Piper Sandler
Jamf competitive threat from Apple is minimal, says Piper Sandler
11/17/21 Bernstein
Apple able to repurchase 3%-4% of shares/year until end of 2026, says Bernstein
NFLX Netflix
$659.68 /

-18.915 (-2.79%)

11/22/21 Wells Fargo
Disney price target lowered to $196 from $203 at Wells Fargo
11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
11/15/21 KeyBanc
Netflix price target raised to $725 from $690 at KeyBanc
11/15/21 JPMorgan
Netflix entering 'strongest content quarter ever,' says JPMorgan
MVRS Meta
/

+

11/19/21 JMP Securities
DoubleVerify may see $200M opportunity from Facebook news, says JMP Securities
11/08/21 Stifel
AMD-Meta partnership shows secular growth thesis 'gaining momentum,' says Stifel
10/28/21 Piper Sandler
Facebook name change a 'big, bold and risky bet,' says Piper Sandler
FB Facebook; also tag MVRS
$341.07 /

-4.29 (-1.24%)

11/09/21 Morgan Stanley
Twitter price target lowered to $62 from $68 at Morgan Stanley
11/09/21 Susquehanna
AMD price target raised to $175 from $145 at Susquehanna
ASTR Astra
$12.11 /

+2.585 (+27.14%)

10/11/21 Deutsche Bank
Astra named short-term investment idea at Deutsche Bank
10/04/21
Fly Intel: Top five analyst initiations
10/04/21 BofA
Astra initiated with an Underperform at BofA
07/27/21 Deutsche Bank
Astra initiated with a Buy at Deutsche Bank
PRVB Provention Bio
$7.26 /

+1.01 (+16.16%)

07/09/21 Chardan
Provention Bio coverage transferred at Chardan
05/28/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
05/25/21 SVB Leerink
Provention Bio briefing documents a positive, says SVB Leerink
05/07/21 Cantor Fitzgerald
Provention Bio price target lowered to $19 from $25 at Cantor Fitzgerald
XPEV XPeng
$47.50 /

+0.64 (+1.37%)

11/11/21 Citi
XPeng price target raised to $87 from $53.40 at Citi
10/28/21
Fly Intel: Top five analyst initiations
10/28/21 Bernstein
Bernstein starts XPeng at Outperform, sees EVs as 'future' of Chinese autos
10/28/21 Bernstein
XPeng initiated with an Outperform at Bernstein
RIVN Rivian Automotive
$111.43 /

-17.21 (-13.38%)

F Ford
$19.90 /

+0.51 (+2.63%)

11/11/21 Morgan Stanley
Morgan Stanley bumps up Ford price target to $12, stays Underweight
11/02/21 Nomura
Nomura downgrades Ford to Reduce, calls premium valuation 'hard to justify'
11/02/21 Nomura
Ford downgraded to Reduce from Neutral at Nomura
10/29/21 Tigress Financial
Snap-On price target raised to $295 from $289 at Tigress Financial
AUPH Aurinia Pharmaceuticals
$20.08 /

-8.41 (-29.52%)

11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
SR Spire
$62.47 /

+0.82 (+1.33%)

11/19/21 Mizuho
Spire price target lowered to $69 from $73 at Mizuho
11/16/21 JPMorgan
Spire downgraded to Neutral from Overweight at JPMorgan
11/08/21
Fly Intel: Top five analyst downgrades
11/08/21 BofA
Spire downgraded to Neutral from Buy at BofA
ELYS Elys Game Technology
$3.37 /

-0.44 (-11.55%)

07/26/21 Maxim
Elys Game Technology initiated with a Buy at Maxim
03/10/21
Fly Intel: Top five analyst initiations
03/10/21 H.C. Wainwright
Elys Game Technology initiated with a Buy at H.C. Wainwright
QIPT Quipt Home Medical
$6.87 /

+0.03 (+0.44%)

11/19/21 Canaccord
Quipt Home Medical price target raised to C$11 from C$10 at Canaccord
11/17/21 Stifel
Quipt Home Medical price target raised to C$12.75 from C$12.40 at Stifel
10/20/21 Benchmark
Quipt Home Medical initiated with a Buy at Benchmark
FNA Paragon 28
$21.90 /

+0.78 (+3.69%)

11/09/21 Canaccord
Canaccord starts foot & ankle share taker Paragon 28 with a Buy
11/09/21 Needham
Paragon 28 initiated with a Buy at Needham
11/09/21 Canaccord
Paragon 28 initiated with a Buy at Canaccord
11/09/21 JMP Securities
Paragon 28 initiated with an Outperform at JMP Securities
TWST Twist Bioscience
$100.90 /

-9.935 (-8.96%)

10/14/21 Cowen
Twist Bioscience coverage transferred at Cowen
08/09/21 Baird
Twist Bioscience price target lowered to $130 from $140 at Baird
06/29/21 William Blair
Twist Bioscience initiated with an Outperform at William Blair
06/04/21
Fly Intel: Top five analyst initiations
GFS GlobalFoundries
$65.00 /

+3.1 (+5.01%)

11/22/21
Fly Intel: Top five analyst initiations
11/22/21 HSBC
GlobalFoundries initiated with a Hold at HSBC
11/22/21 BofA
BofA starts GlobalFoundries at Buy, sees 40% upside potential
11/22/21 JPMorgan
GlobalFoundries initiated with an Overweight at JPMorgan
BLNK Blink Charging
$37.94 /

-5.15 (-11.95%)

11/22/21 Cowen
Blink Charging downgraded to Market Perform from Outperform at Cowen
11/15/21
Fly Intel: Top five analyst upgrades
11/15/21 DA Davidson
Blink Charging price target raised to $35 from $31 at DA Davidson
TDOC Teladoc
$108.83 /

-8.06 (-6.90%)

11/22/21 Stifel
Teladoc price target lowered to $135 from $153 at Stifel
11/22/21 BTIG
Teladoc downgraded to Neutral from Buy at BTIG
11/22/21 BTIG
Teladoc downgraded to Neutral from Buy at BTIG
XEL Xcel Energy
$66.87 /

+1.76 (+2.70%)

11/22/21
Fly Intel: Top five analyst upgrades
11/21/21 BMO Capital
Xcel Energy upgraded to Outperform from Market Perform at BMO Capital
11/02/21 Mizuho
Xcel Energy price target lowered to $64 from $70 at Mizuho
10/29/21 BofA
Xcel Energy upgraded to Buy at BofA following underperformance
XPEV XPeng
$47.50 /

+0.64 (+1.37%)

XEL Xcel Energy
$66.87 /

+1.76 (+2.70%)

VG Vonage
$20.62 /

+4.25 (+25.96%)

TWST Twist Bioscience
$100.90 /

-9.935 (-8.96%)

TSLA Tesla
$1,151.58 /

+15.07 (+1.33%)

TDOC Teladoc
$108.83 /

-8.06 (-6.90%)

STZ.B Constellation Brands; also tag STZ
$239.26 /

+24.95 (+11.64%)

STZ Constellation Brands
$234.69 /

-0.68 (-0.29%)

SR Spire
$62.47 /

+0.82 (+1.33%)

QIPT Quipt Home Medical
$6.87 /

+0.03 (+0.44%)

PRVB Provention Bio
$7.26 /

+1.01 (+16.16%)

NFLX Netflix
$659.68 /

-18.915 (-2.79%)

MNST Monster Beverage
$90.25 /

+0.945 (+1.06%)

FNA Paragon 28
$21.90 /

+0.78 (+3.69%)

FB Facebook; also tag MVRS
$341.07 /

-4.29 (-1.24%)

F Ford
$19.90 /

+0.51 (+2.63%)

ERIC Ericsson
$10.23 /

-0.695 (-6.36%)

ELYS Elys Game Technology
$3.37 /

-0.44 (-11.55%)

CRNC Cerence
$82.95 /

-20.97 (-20.18%)

BLNK Blink Charging
$37.94 /

-5.15 (-11.95%)

AVYA Avaya
$21.70 /

+3.72 (+20.69%)

AUPH Aurinia Pharmaceuticals
$20.08 /

-8.41 (-29.52%)

ATVI Activision Blizzard
$60.69 /

-1.68 (-2.69%)

AAPL Apple
$163.63 /

+3.075 (+1.92%)

  • 10
    Nov
  • 28
    Oct
  • 15
    Oct
  • 14
    Jan
  • 08
    Jan
  • 09
    Dec
  • 03
    Dec
XPEV XPeng
$47.50 /

+0.64 (+1.37%)

VG Vonage
$20.62 /

+4.25 (+25.96%)

TSLA Tesla
$1,151.58 /

+15.07 (+1.33%)

TDOC Teladoc
$108.83 /

-8.06 (-6.90%)

RIVN Rivian Automotive
$111.43 /

-17.21 (-13.38%)

NFLX Netflix
$659.68 /

-18.915 (-2.79%)

MVRS Meta
/

+

MNST Monster Beverage
$90.25 /

+0.945 (+1.06%)

FB Facebook; also tag MVRS
$341.07 /

-4.29 (-1.24%)

ERIC Ericsson
$10.23 /

-0.695 (-6.36%)

BLNK Blink Charging
$37.94 /

-5.15 (-11.95%)

AUPH Aurinia Pharmaceuticals
$20.08 /

-8.41 (-29.52%)

ATVI Activision Blizzard
$60.69 /

-1.68 (-2.69%)

AAPL Apple
$163.63 /

+3.075 (+1.92%)

XPEV XPeng
$47.50 /

+0.64 (+1.37%)

VG Vonage
$20.62 /

+4.25 (+25.96%)

TWST Twist Bioscience
$100.90 /

-9.935 (-8.96%)

TSLA Tesla
$1,151.58 /

+15.07 (+1.33%)

TDOC Teladoc
$108.83 /

-8.06 (-6.90%)

STZ.B Constellation Brands; also tag STZ
$239.26 /

+24.95 (+11.64%)

STZ Constellation Brands
$234.69 /

-0.68 (-0.29%)

RIVN Rivian Automotive
$111.43 /

-17.21 (-13.38%)

PRVB Provention Bio
$7.26 /

+1.01 (+16.16%)

NFLX Netflix
$659.68 /

-18.915 (-2.79%)

MVRS Meta
/

+

MNST Monster Beverage
$90.25 /

+0.945 (+1.06%)

GFS GlobalFoundries
$65.00 /

+3.1 (+5.01%)

FNA Paragon 28
$21.90 /

+0.78 (+3.69%)

FB Facebook; also tag MVRS
$341.07 /

-4.29 (-1.24%)

F Ford
$19.90 /

+0.51 (+2.63%)

ERIC Ericsson
$10.23 /

-0.695 (-6.36%)

CRNC Cerence
$82.95 /

-20.97 (-20.18%)

BLNK Blink Charging
$37.94 /

-5.15 (-11.95%)

AUPH Aurinia Pharmaceuticals
$20.08 /

-8.41 (-29.52%)

ATVI Activision Blizzard
$60.69 /

-1.68 (-2.69%)

ASTR Astra
$12.11 /

+2.585 (+27.14%)

AAPL Apple
$163.63 /

+3.075 (+1.92%)

XPEV XPeng
$47.50 /

+0.64 (+1.37%)

TSLA Tesla
$1,151.58 /

+15.07 (+1.33%)

TDOC Teladoc
$108.83 /

-8.06 (-6.90%)

STZ Constellation Brands
$234.69 /

-0.68 (-0.29%)

RIVN Rivian Automotive
$111.43 /

-17.21 (-13.38%)

QIPT Quipt Home Medical
$6.87 /

+0.03 (+0.44%)

NFLX Netflix
$659.68 /

-18.915 (-2.79%)

MNST Monster Beverage
$90.25 /

+0.945 (+1.06%)

FB Facebook; also tag MVRS
$341.07 /

-4.29 (-1.24%)

F Ford
$19.90 /

+0.51 (+2.63%)

ERIC Ericsson
$10.23 /

-0.695 (-6.36%)

ELYS Elys Game Technology
$3.37 /

-0.44 (-11.55%)

BLNK Blink Charging
$37.94 /

-5.15 (-11.95%)

AVYA Avaya
$21.70 /

+3.72 (+20.69%)

AUPH Aurinia Pharmaceuticals
$20.08 /

-8.41 (-29.52%)

ATVI Activision Blizzard
$60.69 /

-1.68 (-2.69%)

ASTR Astra
$12.11 /

+2.585 (+27.14%)

AAPL Apple
$163.63 /

+3.075 (+1.92%)

AAPL Apple
$163.63 /

+3.075 (+1.92%)

Hot Stocks
Aurinia sinks with buyout speculation seen as 'past its expiration' » 09:42
11/22/21
11/22
09:42
11/22/21
09:42
AUPH

Aurinia Pharmaceuticals

$28.49 /

+ (+0.00%)

Shares of Aurinia…

Shares of Aurinia Pharmaceuticals are falling after the company late Friday filed a prospectus agreement to sell shares. Aurinia also entered a sales agreement, which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250M of common shares that may be issued and sold from time to time under a controlled equity offering sales agreement with Cantor Fitzgerald. Following the news, STAT's Adam Feuerstein tweeted that Aurinia's "buyout speculation looks well past its expiration date." Aurinia Pharmaceuticals shares are down 18% to $23.25 in early trading.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$28.49 /

+ (+0.00%)

AUPH Aurinia Pharmaceuticals
$28.49 /

+ (+0.00%)

11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
AUPH Aurinia Pharmaceuticals
$28.49 /

+ (+0.00%)

AUPH Aurinia Pharmaceuticals
$28.49 /

+ (+0.00%)

AUPH Aurinia Pharmaceuticals
$28.49 /

+ (+0.00%)

AUPH Aurinia Pharmaceuticals
$28.49 /

+ (+0.00%)

Syndicate
Aurinia enters sales agreement prospectus with Cantor for $250M of shares » 09:39
11/22/21
11/22
09:39
11/22/21
09:39
AUPH

Aurinia Pharmaceuticals

$28.49 /

-1.14 (-3.85%)

Aurinia Pharmaceuticals…

Aurinia Pharmaceuticals on Friday filed a registration that contains a base prospectus, which covers the offering, issuance and sale securities identified "from time to time." Aurinia also entered a sales agreement prospectus, which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250M of common shares that may be issued and sold from time to time under a controlled equity offering sales agreement with Cantor Fitzgerald.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

Over a week ago
Syndicate
Aurinia Pharmaceuticals files automatic mixed securities shelf  17:09
11/19/21
11/19
17:09
11/19/21
17:09
AUPH

Aurinia Pharmaceuticals

$28.49 /

-1.14 (-3.85%)

 
ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

AUPH Aurinia Pharmaceuticals
$28.49 /

-1.14 (-3.85%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.